 |
 |
|
 |
||
 |
 |
|
 |
|
|
| Howard McLeod , Pharm. D.
Professor |  |
Recent Accomplishments and Honors
NCI/EORTC visiting fellowship, January, 1993-December, 1994.
American College of Clinical Pharmacy Young Investigator Award. April, 2000.
National Cancer Institute Colorectal Cancer Progress Review Group Roundtable, January, 2000.
American College of Clinical Pharmacy, Elected Fellow. October, 2004.
Training
University of Washington, WA B.Sc. 1988 Pharmacy
Philadelphia College of Pharm. & Science, PA Pharm.D. 1990 Clinical Pharmacology
Publications
Evans WE, McLeod HL. Pharmacogenomics: drug disposition, drug targets, and side effects. N Engl J Med 2003;348:538-549.
Watters JW, McLeod HL. Cancer Pharmacogenomics: current and future applications. Biochem Biophys Acta 2003;1603:99-111.
Mathijssen RHJ, Marsh S, Karlsson MO, Xie R, Baker SD, Verweij J, Sparreboom A, McLeod HL. Irinotecan Pathway Genotype Analysis to Predict Pharmacokinetics. Clin Cancer Res 2003;9:3246-3253.
Xu G, Zhang W, Bertram P, Zheng XF and McLeod HL. Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors. Int J Oncol 2004;24:893-900.
Zhao T, Chang LW, McLeod HL, Stormo GD. PromoLign: A Database for Upstream Region Analysis and SNPs. Hum Mutation 2004;23:534-539.
Wang Y, Jatkoe T, Zhang Y, Mutch MG, Talantov D, Jiang J, McLeod HL, Atkins D. Gene Expression Profiles and Molecular Markers To Predict Recurrence of Dukes B Colon Cancer. J. Clin Oncol 2004;22:1564-1571.
Sparreboom A, Gelderblom H, Marsh S, Ahluwalia R, Obach R, Principe P, Twelves C, Verweij J, McLeod HL.
Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype. Clin Pharmacol Ther. 2004;76:38-44.
Watters J, Kraja A, Meucci M, Province M, McLeod HL. Genome-wide discovery of loci influencing chemotherapy cytotoxicity. Proc Natl Acad Sci USA. 2004;101:11809-11814.
Marsh S, Xiao M, Yu J, Ahluwalia R, Minton M, Freimuth RR, Kwok PY, McLeod HL. Pharmacogenomic assessment of carboxylesterases 1 and 2. Genomics 2004;84:661-668.
King CR, Yu J, Freimuth RR, McLeod HL, Marsh S. Interethnic variability of ERCC2 polymorphisms. Pharmacogenomics J. 2005;5:54-59.
Kidd EA, Yu J, Li X, Shannon WD, Watson MA, McLeod HL. Variance in the Expression of 5-Fluorouracil Pathway Genes in Colorectal Cancer. Clin Cancer Res 2005;11:2612-2619
Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, Blough DK, Thummel KE, Veenstra DL, Rettie AE. Effect of VKORC1 Haplotypes on Transcriptional Regulation and Warfarin Dose. N Engl J Med 2005;352:2285-2293
Marsh S, Mallon MA, Goodfellow P, McLeod HL. Concordance of pharmacogenetic markers in germline and colorectal tumor DNA. Pharmacogenomics. 2005;6:873-877.
Freimuth RR, Xiao M, Marsh S, Minton M, Addleman N, Van Booven DJ, McLeod HL, Kwok PY. Polymorphism discovery in 51 chemotherapy pathway genes. Hum Mol Genet. 2005;14:3595-3603.
Walgren RA, Meucci MA, McLeod HL. Pharmacogenomic discovery approaches: will the real genes please stand up? J Clin Oncol. 2005;23:7342-7349.
McLeod HL, Marsh S. Pharmacogenetics goes 3D. Nat Genet. 2005;37:794-795.
Marsh S, McLeod HL. Pharmacogenomics: from bedside to clinical practice. Hum Mol Genet 2006;15:R89-R93
Zhang W, Shannon WD, Duncan J, Scheffer GL, Scheper RJ, McLeod HL. Expression of drug pathway proteins is independent of tumour type. J Pathol 2006;209:213-219
Frenske TS, McMahon C, Edwin D, Jarvis JC, Cheverud JM, Minn M, Mathews V, Bogue MA, Province MA, McLeod HL, Graubert TA. Identification of Candidate Alkylator Induced Cancer Susceptibility Genes by Whole Genome Scanning in Mice. Cancer Res 2006;66:5029-5038
E-mail: hmcleod@email.unc.edu
Telephone: 919-966-0512
Address: Kerr Hall Chapel Hill, NC 27599
